Friday April 24, 2020
BOULDER — AmideBio LLC, a privately held biopharmaceutical company, announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted an orphan drug designation to AmideBio’s glucagon analog (ABG-023) for the treatment of congenital hyperinsulinism (CHI).
ABG-023 is a solution stable, soluble glucagon analog designed to overcome the limitations of glucagon — an effective treatment for CHI, but rendered impractical for long term administration given its instability in solution.
The development of ABG-023 was funded through Small Business Innovation Research (SBIR) Phase I and II grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Division of the National Institutes of Health (NIH).
“This orphan drug designation is an important step for AmideBio’s development of ABG-023 and for CHI patients and their parents,” said Pawel Fludzinski, CEO and president of AmideBio.
“Glucagon has been shown to be a potentially game-changing treatment for these patients if it can be more readily administered, including for use in pumps.
“Our initial studies of ABG-023 have shown it to have great promise in overcoming the shortfalls of glucagon without sacrificing efficacy. This designation will serve to accelerate our development efforts.”
Congenital hyperinsulinism is a rare disease that affects newborns and children. It results in persistent hypoglycemia which can lead to serious neurological complications including seizures and brain damage.
It is a caused by a defect in the pancreas which results in patients having severe hypoglycemia due to the over production of insulin.